Abstract

The aim of this study was to determine the optimal route of mesenchymal stem cell (MSC) transplantation. To this end, gene expression profiling was performed to compare the effects of intratracheal (IT) versus intravenous (IV) MSC administration. Furthermore, the therapeutic efficacy of each route to protect against neonatal hyperoxic lung injury was also determined. Newborn Sprague-Dawley rats were exposed to hyperoxia (90% oxygen) from birth for 14 days. Human umbilical cord blood-derived MSCs labeling with PKH26 were transplanted through either the IT (5×105) or IV (2×106) route at postnatal day (P) 5. At P14, lungs were harvested for histological, biochemical and microarray analyses. Hyperoxic conditions induced an increase in the mean linear intercept and mean alveolar volume (MAV), indicative of impaired alveolarization. The number of ED-1 positive cells was significantly decreased by both IT and IV transplantations. However, IT administration of MSCs resulted in a greater decrease in MAV and ED-1 positive cells compared to IV administration. Moreover, the number of TUNEL-positive cells was significantly decreased in the IT group, but not in the IV group. Although the IT group received only one fourth of the number of MSCs that the IV group did, a significantly higher number of donor cell-derived red PKH 26 positivity were recovered in the IT group. Hyperoxic conditions induced the up regulation of genes associated with the inflammatory response, such as macrophage inflammatory protein-1 α, tumor necrosis factor-α and inter leukin-6; genes associated with cell death, such as p53 and caspases; and genes associated with fibrosis, such as connective tissue growth factor. In contrast, hyperoxic conditions induced the dwon-regulation of vascular endothelial growth factor and hepatocyte growth factor. These hyperoxia-induced changes in gene expression were decreased in the IT group, but not in the IV group. Thus, local IT MSC transplantation was more effective than systemic IV MSC administration in protecting against neonatal hyperoxic lung injury.

Highlights

  • Bronchopulmonary dysplasia (BPD) is a chronic pulmonary disease that affects very premature infants receiving prolonged ventilator support and oxygen supplementation [1, 2]

  • Human umbilical cord blood (UCB)-derived mesenchymal stem cells (MSC) transplantation into preterm infants is safe and feasible as demonstrated in a phase I dose escalation clinical trial [7]. These findings suggest that transplantation of human UCB-derived MSCs could be a novel therapeutic modality for BPD in premature infants

  • We have previously shown that local intratracheal (IT) transplantation of human UCB-derived MSCs is more effective than systemic intraperitoneal (IP) administration in protecting against neonatal hyperoxic lung injury [4]

Read more

Summary

Introduction

Bronchopulmonary dysplasia (BPD) is a chronic pulmonary disease that affects very premature infants receiving prolonged ventilator support and oxygen supplementation [1, 2]. Novel therapeutic modalities are urgently needed to improve the outcome of this disease. We have shown that administration of human umbilical cord blood (UCB)derived mesenchymal stem cells (MSC) attenuated hyperoxic lung injury in newborn rats [4]. The protective effects of MSC transplantation were shown to be time-dependent [5], and dose-dependent [6]. Human UCB-derived MSC transplantation into preterm infants is safe and feasible as demonstrated in a phase I dose escalation clinical trial [7]. Overall, these findings suggest that transplantation of human UCB-derived MSCs could be a novel therapeutic modality for BPD in premature infants

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call